BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OriCAR-017 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of OriCAR-017\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06182696-3263@assetmemo.bio
DTSTAMP:20261121T005828Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:OriCAR-017: Phase 1/2 readout est. (NCT06182696)
DESCRIPTION:OriCAR-017\, phase 1/2\, Multiple Myeloma.\nStudy: OriCAR-017 C
 himeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
 \nEstimated primary completion: 30 November 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/oricar-017#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06182696
URL:https://assetmemo.bio/drug/oricar-017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06271252-3263@assetmemo.bio
DTSTAMP:20261121T005828Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:OriCAR-017: Phase 1 readout est. (NCT06271252)
DESCRIPTION:OriCAR-017\, phase 1\, Multiple Myeloma.\nStudy: A Study to Eva
 luate the Safety\, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL St
 udy\nEstimated primary completion: 12 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/oricar-017#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06271252
URL:https://assetmemo.bio/drug/oricar-017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
